Thomas Jorgensen
Overview
Explore the profile of Thomas Jorgensen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
298
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Allentoft M, Sikora M, Refoyo-Martinez A, Irving-Pease E, Fischer A, Barrie W, et al.
Nature
. 2024 Jan;
626(7997):E3.
PMID: 38238538
No abstract available.
2.
Allentoft M, Sikora M, Refoyo-Martinez A, Irving-Pease E, Fischer A, Barrie W, et al.
Nature
. 2024 Jan;
625(7994):301-311.
PMID: 38200295
Western Eurasia witnessed several large-scale human migrations during the Holocene. Here, to investigate the cross-continental effects of these migrations, we shotgun-sequenced 317 genomes-mainly from the Mesolithic and Neolithic periods-from across...
3.
Allentoft M, Sikora M, Fischer A, Sjogren K, Ingason A, Macleod R, et al.
Nature
. 2024 Jan;
625(7994):329-337.
PMID: 38200294
Major migration events in Holocene Eurasia have been characterized genetically at broad regional scales. However, insights into the population dynamics in the contact zones are hampered by a lack of...
4.
Prentoe J, Janitzek C, Velazquez-Moctezuma R, Soerensen A, Jorgensen T, Clemmensen S, et al.
NPJ Vaccines
. 2022 Nov;
7(1):148.
PMID: 36379958
Development of B-cell-based hepatitis C virus (HCV) vaccines that induce broadly neutralizing antibodies (bNAbs) is hindered by extensive sequence diversity and low immunogenicity of envelope glycoprotein vaccine candidates, most notably...
5.
Burcharth J, Abdulhady L, Danker J, Ekeloef S, Jorgensen T, Lauridsen H, et al.
Eur J Trauma Emerg Surg
. 2019 Oct;
47(2):467-477.
PMID: 31628502
Purpose: Enhanced recovery after surgery programs is widely implemented in elective settings, however, until recently, rarely in emergency surgery. The purpose of this study was to present detailed contents and...
6.
Healer J, Wong W, Thompson J, He W, Birkinshaw R, Miura K, et al.
Cell Microbiol
. 2019 Apr;
21(7):e13030.
PMID: 30965383
An effective vaccine is a priority for malaria control and elimination. The leading candidate in the Plasmodium falciparum blood stage is PfRh5. PfRh5 assembles into trimeric complex with PfRipr and...
7.
Wong W, Huang R, Menant S, Hong C, Sandow J, Birkinshaw R, et al.
Nature
. 2018 Dec;
565(7737):118-121.
PMID: 30542156
Plasmodium falciparum causes the severe form of malaria that has high levels of mortality in humans. Blood-stage merozoites of P. falciparum invade erythrocytes, and this requires interactions between multiple ligands...
8.
Lennartz F, Brod F, Dabbs R, Miura K, Mekhaiel D, Marini A, et al.
Nat Commun
. 2018 Sep;
9(1):3822.
PMID: 30237518
The quest to develop an effective malaria vaccine remains a major priority in the fight against global infectious disease. An approach with great potential is a transmission-blocking vaccine which induces...
9.
Jin J, Tarrant R, Bolam E, Angell-Manning P, Soegaard M, Pattinson D, et al.
NPJ Vaccines
. 2018 Aug;
3:32.
PMID: 30131879
reticulocyte-binding protein homolog 5 (PfRH5) is a leading asexual blood-stage vaccine candidate for malaria. In preparation for clinical trials, a full-length PfRH5 protein vaccine called "RH5.1" was produced as a...
10.
Payne R, Silk S, Elias S, Milne K, Rawlinson T, Llewellyn D, et al.
JCI Insight
. 2017 Jun;
2(12).
PMID: 28614791
Background: Plasmodium vivax is the most widespread human malaria geographically; however, no effective vaccine exists. Red blood cell invasion by the P. vivax merozoite depends on an interaction between the...